Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study

Silvana Galderisi1, Marc De Hert1,2,3,4, Stefano Del Prato5, Andrea Fagiolini6, Philip Gorwood7, Stefan Leucht8, Aldo Pietro Maggioni9, Armida Mucci1 and Celso Arango10

1Department of Psychiatry, University of Campania Luigi Vanvitelli, Naples, Italy; 2University Psychiatric Centre—KU Leuven, Kontenberg, Belgium; 3Department of Neuroscience, KU Leuven, Kontenberg, Belgium; 4Antwerp Health Law and Ethics Chair, AHLEC University Antwerpen, Antwerp, Belgium; 5Department of Clinical and Experimental Medicine, Section of Metabolic Diseases and Diabetes, University of Pisa, Pisa, Italy; 6Department of Molecular Medicine, Division of Psychiatry, University of Siena, Siena, Italy; 7INSERM U1266, Institute of Psychiatry and Neurosciences of Paris (IPNP) & GHU Paris Psychiatrie et Neurosciences (CMME, Sainte-Anne Hospital), Université de Paris, Paris, France; 8Department of Psychiatry and Psychotherapy, School of Medicine, Technische Universität München, Munich, Germany; 9Maria Cecilia Hospital, GYM Care & Research, Cotignola, Ravenna, Italy and 10Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Gregorio Marañón, IDSM, School of Medicine, Universidad Complutense, CIFERSAM, Madrid, Spain

Abstract

Background: Patients with schizophrenia spectrum disorders (SSD) have worse physical health and reduced life expectancy compared to the general population. In 2009, the European Psychiatric Association, the European Society of Cardiology and the European Association for the Study of Diabetes published a position paper aimed to improve cardiovascular and diabetes care in patients with severe mental illnesses. However, the initiative did not produce the expected results. Experts in SSD or in cardiovascular and metabolic diseases convened to identify main issues relevant to management of cardiometabolic risk factors in schizophrenia patients and to seek consensus through the Delphi method.

Methods: The steering committee identified four topics: 1) cardiometabolic risk factors in schizophrenia patients; 2) cardiometabolic risk factors related to antipsychotic treatment; 3) differences in antipsychotic cardiometabolic profiles; 4) management of cardiometabolic risk. Twelve key statements were included in a Delphi questionnaire delivered to a panel of expert European psychiatrists.

Results: Consensus was reached for all statements with positive agreement higher than 85% in the first round. European psychiatrists agreed on: 1) high cardiometabolic risk in patients with SSD; 2) importance of correct risk management of cardiometabolic diseases, from lifestyle modification to treatment of risk factors, including the choice of antipsychotic drugs with a favourable cardiometabolic profile. The expert panel identified the psychiatrist as the central coordinating figure of management, possibly assisted by other specialists and general practitioners.

Conclusions: This study demonstrates high level of agreement among European psychiatrists regarding the importance of cardiovascular risk assessment and management in subjects with SSD.

Introduction

Patients with severe mental illness, such as schizophrenia, have worse physical health and reduced life expectancy compared to the general population [1]. Life expectancy of patients with schizophrenia is reduced 14.5 years [2] and this excess mortality is mainly due to cardiovascular causes and obesity-related cancers [3].

The development of cardiovascular diseases (CVD) and the excess cardiovascular mortality observed in these patients are associated with a number of modifiable cardiometabolic risk factors: abdominal obesity, high blood pressure, low level of high-density lipoprotein cholesterol, elevated triglycerides, and hyperglycaemia [4, 5]. This cluster of risk factors, considered as a whole, defines the so-called metabolic syndrome (MetS).

The association between schizophrenia and cardiometabolic risk factors is complex and determined by an inter-relationship between environmental factors (lifestyle and difficulty in accessing treatments), genetic vulnerability, and disease-related factors [6]; moreover,
antipsychotic treatment represents an important contributor to risk of cardiometabolic dysfunction, particularly for certain drugs in vulnerable patients [7, 8].

Evidence of genetic determinants of the cardiometabolic risk in schizophrenia includes the identification of shared genetic traits between schizophrenia and diabetes mellitus or insulin resistance [9, 10], as well as an increased incidence of cardiometabolic risk factors in unaffected relatives of patients with schizophrenia and in antipsychotic-naïve patients [11, 12].

In 2009, the European Psychiatric Association (EPA), together with the European Society of Cardiology and the European Association for the Study of Diabetes, published a position paper with the aim to reduce modifiable CVD risk factors, improve diabetes care, and overall health in patients with severe mental illnesses [4].

In the following years, several meta-analyses and cohort studies have been published which highlighted the severity of cardiometabolic risk and diseases among patients with schizophrenia [13, 14]. Guidelines on cardiometabolic risk management in these patients were also produced [6]. Moreover, in 2014 and 2018, European [15] and American guidances regarding tobacco dependence and strategies for smoking cessation [16] and European guidance for physical activities [17] were published. However, all these recommendations have not sufficiently translated into clinical practice to a degree that is proportional to their importance.

A retrospective cohort analysis showed that screening of plasma lipid and glucose levels in patients taking antipsychotics remained low after the publication of specific monitoring guidelines, despite a significant increase with respect to the period preceding the guidelines publication [18]. More recently, two different studies analyzed the adherence of clinicians to the guidelines on cardiovascular and metabolic monitoring and demonstrated poor monitoring of cardiac function [19] and suboptimal monitoring of metabolic risk in patients treated with antipsychotics [20].

Finally, a recent meta-analysis of prospective studies in patients with psychiatric disorders on monitoring, diagnosis, control of risk factors, and treatment of CVD showed an association of schizophrenia with a low probability of having the smoking habit recorded, a diagnosis of hypertension, as well as treatment with antihypertensive and lipid-lowering drugs [21].

This gap needs to be addressed, given the stunning and unequivocal evidence of its priority.

The aim of this study was to evaluate the consensus level of a representative group of European psychiatrists on a series of statements regarding the assessment and the management of cardiometabolic risk factors in patients with schizophrenia.

Methods

A Steering Committee, consisting of re-known experts in the fields of diagnosis and treatment of schizophrenia (CA, MDH, AF, SG, PG, SL), diabetes and metabolic diseases Stefano Del Prato (SDP) and cardiovascular diseases (APM), Aldo Pietro Maggioni (APD) coming from different European countries, based on research evidence and clinical judgment selected the main topic of interest (cardiometabolic morbidity in patients with schizophrenia spectrum disorder) and then identified the following four main sub-topics: (a) cardiometabolic risk factors in naïve and treated schizophrenic patients; (b) cardiometabolic risk factors related to antipsychotic treatment; (c) differences in the cardiometabolic profiles among antipsychotics; (d) management of cardiometabolic risk with a specific focus on tobacco use. Fourteen statements related to the above topics were then developed by the steering committee.

After further review the total number of statements were reduced to 12 (Table 1) and endorsed by all the members of the steering committee. The statements were then submitted to a validation panel (see Acknowledgment for panel members’ names) for revision/approval.

After an in-depth discussion of the feedback received from the validation panel, the final questionnaire was approved.

The Delphi questionnaire initially developed in English was then translated into four other European languages (French, German, Italian, and Spanish), in order to ensure participants’ maximum understanding.

Delphi method and participants

The questionnaire was delivered to an expert panel of 191 European psychiatrists using a modified Delphi method [22].

Participants were experts in the treatment of schizophrenia, selected on the basis of their scientific production or from the members of the EPA Schizophrenia section and European College of Neuropsychopharmacology Schizophrenia network, from all geographical regions of Europe. As experts of the consensus topics and mostly active clinicians in their different countries/regions, they could have an impact on the practice of their colleagues in the real world in different ways; among others, their role in medical and psychiatric training, as well as in continuous medical education, especially for those from academia settings.

The panel of experts had to include at least 30% of females.

For each statement of the questionnaire, the expert had to express his/her level of agreement according to the following 5-point Likert scale: 1 = strongly disagree; 2 = disagree; 3 = agree; 4 = more than agree; 5 = strongly agree. In accordance with the Delphi standards, consensus is reached when the sum of items 1 and 2 (Disagree) or that of 3, 4, and 5 (Agree) reaches 66%. No consensus is reached, when the sum of the responses for a negative consensus (1 and 2) or a positive consensus (3, 4, and 5) is <66% [18].

The panel of experts received an invitation email containing a brief introduction to the project with its objectives and process, and a link to the on-line questionnaire. The deadline for compiling the questionnaire was set after 14 days from the invitation and reminder emails were sent after 1 week, followed by reminder emails sent every 3 days. After deadline, with the aim of reaching the highest response rate, a one-week extension for filling in the Delphi questionnaire was granted.

No personal data were collected from the panel of experts, with the exception of the email addresses that were used only for sending invitation and reminder emails. All the data from the questionnaire were analyzed in an anonymous way.

Results

One-hundred twenty-two panelists from 27 European countries out of the selected 191 (64%) completed the Delphi questionnaire. Answers to the questionnaire are shown in Table 1.

Panelists’ agreement on statements was very high in the first round of the Delphi Study. Consensus was reached for all statements (Table 1), with a percentage of positive agreement higher than 85% on each statement, suggesting a shared view of European psychiatrists on the proposed topics. A strong agreement (responses 4 and 5) was reached with a percentage ≥ 70% on all statements except one, for which it was 61%. This latter statement
Table 1. Percentage of agreement on each statement of the Delphi questionnaire.

| Statement                                                                 | Percentage (numbers) of responses for each level of agreement | Percentage of negative consensus (1–2 responses) | Percentage of positive consensus (3–5 responses) | Percentage of strong positive consensus (4–5 responses) |
|---------------------------------------------------------------------------|---------------------------------------------------------------|-------------------------------------------------|--------------------------------------------------|--------------------------------------------------------|
| 1. Subjects with schizophrenia or other severe mental disorders have more than 80% higher risk of death from CV diseases compared to the general population. Therefore, the routine assessment and monitoring of CV risk should be mandatory in these subjects. | 1% (1) 1% (1) 13% (16) 31% (38) 54% (66) 2% 98% 85% |                                                 |                                                 |                                                        |
| 2. The presence of a schizophrenia spectrum disorder should be considered an additional risk factor for CV | 0% (0) 5% (6) 23% (28) 42% (51) 30% (37) 5% 95% 72% |                                                 |                                                 |                                                        |
| 3. Psychiatrists should assess the level of CV risk of all patients with a schizophrenia spectrum disorder with the indication to be treated with an antipsychotic agent, following the recommendations of the EPA position paper | 0% (0) 2% (3) 14% (17) 43% (52) 41% (50) 2% 98% 84% |                                                 |                                                 |                                                        |
| 4. All patients with the indication to be treated with an antipsychotic agent should receive education on CV risk factors and proper lifestyle modification, including physical exercise and weight reduction. | 0% (0) 0% (0) 11% (14) 21% (26) 68% (82) 0% 100% 89% |                                                 |                                                 |                                                        |
| 5. Relatives of patients with the indication to be treated with an antipsychotic agent should receive education on CV risk factors and proper lifestyle modification, including physical exercise and weight reduction, if patients consent to involve them. | 2% (2) 3% (4) 19% (23) 29% (36) 47% (57) 5% 95% 76% |                                                 |                                                 |                                                        |
| 6. Clinicians should inform about, facilitate or initiate validated strategies for smoking cessation in all patients with a schizophrenia spectrum disorder, because of their increased risk for severe tobacco use disorder, contributing to their high morbidity and mortality rates. | 1% (1) 2% (2) 15% (19) 29% (36) 53% (64) 3% 97% 82% |                                                 |                                                 |                                                        |
| 7. Screening and monitoring metabolic risk factors should be more frequent after the initiation of an antipsychotic drug. | 0% (0) 1% (1) 7% (9) 33% (40) 59% (72) 1% 99% 82% |                                                 |                                                 |                                                        |
| 8. Antipsychotics differ in their cardio-metabolic risk. The risk of weight gain and cardio-metabolic side effects, together with efficacy and other side effect profile, should guide the choice of an antipsychotic. | 0% (0) 1% (1) 11% (13) 38% (47) 50% (61) 1% 99% 88% |                                                 |                                                 |                                                        |
| 9. Wherever possible, use drugs with low cardio-metabolic risk starting from the acute treatment phase. When this is not possible, due to concerns about efficacy and/or other side effects, and cardio-metabolic side effects are significant, consider antipsychotic switch during maintenance treatment. | 2% (2) 4% (5) 19% (23) 32% (40) 43% (52) 6% 94% 75% |                                                 |                                                 |                                                        |
concerned the central role of psychiatrists in the management of cardiovascular and metabolic risk factors in subjects with schizophrenia spectrum disorders.

Discussion

The aim of this study was to evaluate the consensus level of a representative group of European psychiatrists about a series of statements pertaining to the assessment and management of cardiometabolic risk factors in patients with schizophrenia spectrum disorders. The statements were primarily based on the recommendations reported in the EPA position paper and guidance, which were integrated with the most recent evidence.

The Delphi questionnaire was sent to 191 psychiatrists from all over European countries and, despite the COVID 19 emergency, the response rate was sufficiently high (64%).

Statements 1 and 2: Cardiometabolic Risk in Patients with Schizophrenia Spectrum Disorders

Ninety-eight and 95% of participants agreed that patients with schizophrenia spectrum disorders are at higher risk for CVD and related death and that schizophrenia should be considered a risk factor for CVD in itself, respectively. These statements are supported by a high level of evidence. Patients with severe mental illnesses such as schizophrenia have a mortality risk increased by two or three fold compared to the general population [3] with a 20% decrease in life expectancy [23]. The excess mortality is largely due to CVD; in fact, people with schizophrenia have nearly twice the normal risk of dying from CVD [23]. The development of CVD and the excess of mortality in these patients seem to be associated with a higher incidence of MetS [24–26].

In people with schizophrenia, the prevalence of MetS is about 30% and the onset is 10 years earlier than in the general population [25]. Moreover, the prevalence of all the traits of the MetS is two or three times greater in the psychiatric population than in the general population [1, 5]. The higher incidence of MetS is generally related to several factors: genetic, behavioral (dietary factors, reduced physical activity, smoking habit), pharmacological (antipsychotics) [5], and reduced access to healthcare (partially justified by patients’ socioeconomic status).

As to lifestyle factors, there is a high prevalence of poor diet, smoking, and inadequate exercise among patients with severe psychiatric disorders. A cross-sectional study showed that many patients did not follow the recommendations for diet and daily exercise in spite of being aware of their unhealthy lifestyles. Thus, there is potential for interventions to improve lifestyle factors and, through this, reduce the risk of cardiometabolic disease [23].

Socioeconomic status and lifestyle do not completely explain the increased risk. Serious mental illnesses (such as schizophrenia spectrum disorders) and in general psychotic symptoms seem to have a strong association with several somatic illnesses [12, 27]. This association may be explained by the existence of a pathophysiological link based on genetic, inflammatory, immunological, and/or metabolic mechanisms.

Data from drug-naïve patients with schizophrenia suggest that an intrinsic metabolic risk, leading to increased incidence of CVD, is associated with the disease, most likely due to a common genetic basis [11]. Recent studies have demonstrated that schizophrenia and type 2 diabetes share genetic mechanisms that at least partially justify their concomitance [9]. In addition, it has been reported that
an inherited predisposition of patients with schizophrenia to psycho-neuroendocrine dysfunction may confer increased risk of type 2 diabetes and MetS [10]. Finally, impaired glucose tolerance has been demonstrated in non-psychotic, first-degree relatives of patients with schizophrenia, further indicating an association between MetS and psychosis genetic risk [11].

Statement 4, 5, 7: Cardiometabolic Risk Assessment and Management

More than 80% of participants strongly agreed (responses 4 and 5) that all patients with the indication of antipsychotic treatment and their relatives should be educated on CVD risk factors and proper lifestyle modification, including physical exercise, weight reduction, and smoking cessation.

As for the previous statements, a high level of evidence supports these statements. Psychiatric patients move less and adhere less to the prescriptions of correct physical activity; among these patients, people with schizophrenia were the least physically active [24]. The beneficial effect of a combination of healthy lifestyle behaviors for the primary prevention of MetS has been proven in the general population [28].

The World Psychiatric Association (WPA) recommends that psychiatrists and other members of the multidisciplinary team educate and motivate patients with schizophrenia to improve their lifestyle through the use of behavioral interventions, including smoking cessation, dietary measures, and physical exercise [6].

The available guidelines [6, 29] recommended that, since patients with schizophrenia represent a high-risk group for developing cardiometabolic abnormalities, they should be routinely screened for CVD risk factors at all stages of the disorder.

The risk assessment must be carried out during the first visit and before the prescription of antipsychotic treatment. In patients without other metabolic risk factors treated with antipsychotics, the EPA position paper and WPA guidelines [4, 29] recommend monitoring the CVD risk factors after 6 and 12 weeks and then every 12 months to assess the risk profile of the administered drug. If other risk factors are present, more frequent monitoring should be considered. Many of the MetS risk factors are modifiable. It is therefore recommended to treat any risk factor (hypertension, hypercholesterolemia, etc.), possibly involving the general practitioner and the psychiatrist.

Statement 3, 10, 11: Coordination of Cardiometabolic Risk Assessment and Management

Ninety-eight percent of participants agreed that the psychiatrist should assess the CVD risk of patients with a schizophrenia spectrum disorder with the indication of an antipsychotic treatment but only 60% of them strongly agreed (responses 4 and 5) that psychiatrists should also be in charge of the management of cardiovascular and metabolic risk factors in subjects with schizophrenia spectrum disorders.

In conclusion, the evidence showed that patients with schizophrenia want to quit as much as the general population and that available treatments work as they do in the general population. Therefore, smoking cessation interventions must be promoted.

Statement 6: Smoking and Mortality Risk

Eighty-two percent of the panelists strongly agreed (responses 4 and 5) that patients with schizophrenia spectrum disorders are at increased risk for severe tobacco use disorder and that this contributes to their high morbidity and mortality rates. For this reason, they agreed that clinicians should inform the patients about validated strategies for smoking cessation and facilitate or initiate them in these patients.

About 2/3 of patients with schizophrenia have a smoking habit (33%), frequently start smoking at an earlier age and are heavier smokers than the general population [34, 35]. These factors contribute to the high levels of morbidity in this population [36]. In particular, tobacco consumption is associated with cardiovascular risk, and mortality data in patients with schizophrenia demonstrated a 12-fold increase in the odds of cardiac related deaths in smokers as compared to non-smokers [36].

The smoking habit has an important genetic component (i.e., a high heritability) and a single gene explains 14% of the risk of being a smoker or a non-smoker [37]. This is the first case in psychiatry where a single gene accounts for such a high percentage of risk. Moreover, looking at the polygenic risk score in schizophrenia and nicotine dependence, a genetic overlap is observed between the two conditions [38].

A study has demonstrated that the motivation to quit is as high among psychiatric patients as in the general population [15].

Moreover, looking at pharmacological therapies for smoking cessation, a meta-analysis of 28 RCTs calculated the risk ratio of smoking cessation at 3 months showing that the efficacy and persistence of the effect are the same in patients with schizophrenia than they are in the general population, with a very low number needed to treat [39].

In conclusion, the evidence showed that patients with schizophrenia want to quit as much as the general population and that available treatments work as they do in the general population. Therefore, smoking cessation interventions must be promoted.

Statement 8, 9: Antipsychotics and Cardiometabolic Risk

Along with additional lifestyle and environmental factors, the combination of antipsychotic treatment and intrinsic risk factors leads to the serious metabolic dysfunctions described in these patients [11].
Eighty-eight percent of participants widely agreed (responses 4 and 5) that the cardiometabolic profile of an antipsychotic should guide the choice of treatment, together with efficacy and other side effects profile. Seventy-five percent strongly agreed (responses 4 and 5) that wherever possible, drugs with low cardiometabolic risk should be preferred both in acute or, if not possible, in chronic treatment.

It is well known that antipsychotics negatively impact on MetS risk factors (e.g., they are linked to insulin resistance, diabetes/hyperglycemia, dyslipidemia, overweight/obesity) [44]. Most of them induce weight gain [10]. Although it is well known that not all antipsychotics have the same impact on MetS and on its traits [1, 45].

Recent studies showed a marked difference among antipsychotics in terms of effects on weight [46] and metabolic side-effects, with olanzapine and clozapine exhibiting the worst profiles and aripiprazole, cariprazine, lurasidone, and ziprasidon the most favorable ones [47].

Many mechanisms are implicated in the metabolic impact of the various antipsychotics, from their effect on histamine receptors, to an action on serotonin [11, 48, 49], to an indirect effect of dopamine on prolactin release and consequently the regulation of estradiol, progesterone, and testosterone metabolism [50].

From a molecular point of view, the side effects as well as the effectiveness of antipsychotics are linked to their specific binding profile with the receptors. Antipsychotics have different receptor affinity profiles and the individual molecules have different receptor affinities depending on the dosage; the binding profile of the drugs therefore depends on the level of the drugs itself in the plasma and brain [51, 52].

The antipsychotic-induced metabolic abnormalities also show a high interindividual variability suggesting the presence of genetic determinants [1, 53, 54]. Based on the above evidence, the choice of an antipsychotic should be made on an individual basis, taking into consideration the safety profile of the different antipsychotics, accurately weighing the risk of major adverse effects, for example, intolerance to extrapyramidal side effects which increases the risk of tardive dyskinesia [56], or presence of family risk factors for metabolic abnormalities which increases the risk of CVD.

In general, addressing medical comorbidity should be part of the routine care of patients and safety concerns should be one of the main drivers of antipsychotic prescriptions [55].

Conclusions

European psychiatrists agreed that patients with schizophrenia spectrum disorders are at greater CVD risk. Lifestyle, socioeconomic level, and genetic background play a role in this risk.

In line with the EPA recommendations and the most recent evidence, the surveyed psychiatrists agreed on the importance of an early identification of CVD risks and illness, which should be coupled with an immediate implementation of appropriate risk management strategies. The development of lifestyle interventions to prevent and treat CVD in patients with schizophrenia spectrum disorders is paramount. The cardio-metabolic risk profile of each antipsychotic should be one of the main informants for treatment choice. In general, they have identified the central coordinating figure of this management in the psychiatrist, but the need for a team effort including the specialists as well as the general practitioner must be encouraged.

Not surprisingly, but yet very importantly, 99% of the surveyed psychiatrists agreed that translating the EPA recommendations on CVD risk into routine clinical practice is a priority in the management of patients with schizophrenia spectrum disorders.

Members of the Validation Panel

Paola Bucci (Italy), Alain Dervaux (France), Alkomiet Hasan (Germany), Stephan Heres (Germany), Antonio Vita (Italy), Florence Vorspan (France).

Participants in the Delphi Process

Katryn Abrahms (Belgium), Young Allan (UK), Mario Amore (Italy), Karow Ann (Germany), Daniil Aptalidis (Bulgaria), Massimo Ballerini (Italy), Josef Bäuml (Germany), István Bitter (Hungary), Julio Bobes (Spain), Laurynas Bukelskis (Lithuania), Marc Calmelyn (Belgium), Mary Cannon (Ireland), Kirtsen Cathor (Belgium), Dan Cohen (Netherlands), Anna Comparelli (Italy), Eric Constant (Belgium), Valentina Corigliano (Italy), Christoph Correll (Germany), Eijinde D’op’t (Netherlands), Karlovic Dalibor (Croatia), Paola Dazzan (UK), Sergio De Filippis (Italy), Dirk De Wachter (Belgium), Jurgen Defruyt (Belgium), Sonia Dollfus (France), Elena Dragioti (Sweden), Caroline Dubertret (France), Bjorn Edbrup (Denmark), Ganze Erzin (Turkey), Saana Eskelinen (Finland), Peter Falkai (Germany), Gerardo Favaretto (Italy), Emilio Fernandez-Egea (UK), Maria Luisa Figueira (Portugal), Slechtn Floris (Netherlands), Petros Fotiadis (Greece), Kostas Fountoulakis (Greece), David Fraguas (Spain), Maria Paz Garcia-Portilla (Spain), Reynolds Gavin (UK), Inez Germey (Belgium), Benoit Gillain (Belgium), Sladjana Gluscevic (Serbia), Xenia Gonda (Hungary), Guy Goodwin (UK), Eufroynes Gouzoulis-Mayfrank (Italy), Iria Grande (Spain), Eric Hanh (Germany), Alex Hofer (Austria), Birgit Jansen (Germany), Marek Jarema (Poland), Natalia Jimeno (Spain), Peter Jones (UK), Stefan Kaiser (Switzerland), Frederic Kochman (France), Anna Kuranova (Netherlands), Martin Lambert (Germany), Christophe Lançon (France), Berthold Langguth (Germany), Marion Leboyer (France), Dusica Lecic Tosevski (Serbia), Karolina Leopold (Germany), Jan Libiger (Czech R.), Pierre-Michel Llorca (France), Maria Paz Long (UK), Claudio Luci (Italy), Bak Maarten (Netherlands), Piero Antonio Magnani (Italy), Jasmina Mallet (France), Nadja P Maric (Serbia), Andre Masson (Belgium), Celine Matton (Belgium), Mauro Mauri (Italy), Ingrid Melle (Norway), Thomas Messer (Germany), Andrea Meyer-Lindenberg (Germany), Tim Moons (Belgium), Dieter Naber (Germany), Stefano Nansini (Italy), Alyydas Navickas (Lithuania), Mette Ødegaard Nielsen (Denmark), Philippe Nuss (UK), David Nutt (UK), Georgios Papazizis (Greece), Jozef Peuskens (Belgium), Stefan Priebe (UK), Goran Racetovic (Bosnia), Elmars Rancans (Latvia), Anita Riecher-Rössler (Switzerland), Martina Rojnic (Croatia), Janusz K Rybakowski (Poland), Gabriele Sachs (Austria), Myrto Samara (Greece), Jerzy Samochowiec (Poland), I San (Spain), Norman Sartorius (Switzerland), Nikolaos Smyrnis, (Greece), Daria Smirnova (Russia), Iris Sommer (Netherlands), Geerke Steegen (Belgium), Drozdostoy Stoyanov (Bulgaria), Jaana Suvisaari (Finland, Agata Szulc (Poland), Thi-Minh-Tam Ta (Germany), Pierre Thomas (France), Jari Tiihonen (Finland), Sarah Tosato (Italy), Alp Ucok (Turkey), Marie Noelle Vacheron (France), Ruud Van Winkel (Belgium), Veronica Velasco Gonzalez (Spain), Helene Verdoux (France), Domagoj Vidovic (Croatia), Eduard Vieta (Spain), Vincenzo Villari (Italy), Jelena Vrublevska (Latvia), Oliva Vukoci (Serbia), Marcin Wojnar (Poland), Aysegul Yildiz (Turkey), Alessandro Zuddas (Italy).

Acknowledgment. The authors wish to thank Ethos sfrl for logistic support in conducting the Delphi study.
Financial Support. The work has been carried out thanks to an unrestricted grant from Angelini. CA was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SA16160P17CP1, P116/02012, P119/024), co-financed by ERDF Funds from the European Commission, “A way of making Europe,” CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GED), FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIDS-2-TRIALS), Fundación Familia Alonso and Fundación Alícia Koplowitz.

Conflict of Interest. S. Galderisi has been a consultant and/or advisor to or has received honoraria or expenses from: Millennium Pharmaceuticals, Innova Pharma-Recordati Group, Janssen Pharmacuetica NV, Sunovion Pharmaceuticals, Janssen-Cilag Polska, Gedeon-Richter-Recordati, Pierre Fabre, Otsuka, Lundbeck Italia and Angelini- Acraf outside the submitted work. A.P. Maggioni received personal fees for the participation in committees of studies sponsored by Bayer, Fresenius, Novartis outside the present work. C. Arango. has been a consultant to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen Cilag, Lundbeck, Minerva, Otsuka, Roche, Sage, Servier, Shire, Schering Plow, Sumitomo Dainippon Pharma, Sunovion and Takeda. P. Gorwood received during the last 5 years fees for presentations at congresses or participation in scientific boards from Alcedag-Alcen, Angelini, GSK, Janssen, Lundbeck, Otsuka, SAGE and Servier. A. Mucci acted as an independent consultant of Ethos srl in this project. She received honoraria, advisory board or consulting fees, outside the present work, from the following companies: Angelini- Acraf, Astra Zeneca, Bristol-Myers Squibb, Gedeon Richter Bulgaria, Innova-Pharma, Janssen Pharmaceuticals, Lundbeck, Otsuka, Pfizer and Pierre Fabre. M. de Hert has no competing interests.

Authorship Contributions. All the authors contributed to the manuscript. All the authors contributed to formulating the questionnaire, analyzing the responses, and made critical revisions of the manuscript.

Data Availability Statement. The data that support the findings of this study are available from the corresponding author, SG, upon reasonable request.

References

[1] De Hert M, Schreurs V, Vancampfort D, Van Winkel R. Metabolic syndrome in people with schizophrenia: a review [published correction appears in World Psychiatry. 2011 Feb;10(1):78]. World Psychiatry. 2009; 8(1):15–22.

[2] Hjorthøj C, Sturup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis [published correction appears in Lancet Psychiatry. 2017 Sep;4(9): e19]. Lancet Psychiatry. 2017; 4(4):295–301.

[3] De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10:52–77.

[4] De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Möller HJ. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry. 2009;24(6): 412–24.

[5] Vancampfort D, Wamper M, Mitchell AJ, Correll CU, De Herdt A, Probst M, et al. A meta-analysis of cardio-metabolic abnormalities in drug naive, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry. 2013;12(3):240–50.

[6] De Hert M, Vancampfort D, Correll CU, Mercken V, Peuskens J, Sweers K, et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry. 2011;199(2):99–105.

[7] Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand. 2009;119(3): 171–9.

[8] Arango C, Bobes J, Aranda P, Carmena R, Garcia-Garcia M, Rejas J, et al. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. Schizophr Res. 2008;104(1–3):1–12.

[9] Hackinger S, Prins B, Mamakou V, Zengini E, Marouli E, Brčić L, et al. Evidence for genetic contribution to the increased risk of type 2 diabetes in schizophrenia. Transl Psychiatry. 2018;8(1):252. Published 2018 Nov 23.

[10] Postolache TT, Del Bosque-Plata L, Jabbour S, Vergare M, Wu R, Gragnoli C. Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome. Am J Med Genet B Neuropsychiatr Genet. 2019; 180(3):186–203.

[11] Freyberg Z, Aslanoglou D, Shah R, Ballon JS. Intrinsic and antipsychotic drug-induced metabolic dysfunction in schizophrenia. Front Neurosci. 2017;11:432. Published 2017 Jul 28.

[12] Moreno C, Nuevo R, Chatterji S, Verdes E, Arango C, Ayuso-Mateos JL. Psychotic symptoms are associated with physical health problems independently of a mental disorder diagnosis: results from the WHO World Health Survey. World Psychiatry. 2013;12(3):251–7.

[13] Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry. 2014;71(12):1350–63.

[14] Howell S, Varovova E, Khwanda A, Rosen SD. Cardiovascular effects of psychotic illnesses and antipsychotic therapy. Heart. 2019;105(24): 1852–9.

[15] Rütter T, Bobes J, De Hert M, Svensson TH, Mann K, Batra A, et al. EPA guidance on tobacco dependence and strategies for smoking cessation in people with mental illness. Eur Psychiatry. 2014;29(2):65–82.

[16] Centers for Disease Control and Prevention. Best practices for comprehensive tobacco control programs—2014. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.

[17] Stubbs B, Vancampfort D, Hallgren M, Firth J, Veronese N, Solmi M, et al. EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and position statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). Eur Psychiatry. 2018;54:124–44.

[18] Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry. 2009; 166(3):345–53. doi: 10.1176/appi.ajp.2008.08033833. Epub 2009 Jan 15. PMID: 19147694.

[19] Manchia M, Firinu G, Carpinelli B, Pinna F. Clinicians’ adherence to clinical practice guidelines for cardiac function monitoring during anti-psychotic treatment: a retrospective report on 434 patients with severe mental illness. BMC Psychiatry. 2017;17(1):121. doi: 10.1186/s12888-017-1289-7. PMID: 28359306; PMCID: PMC5374645.

[20] Pereira I, Budovich A, Claudio-Saez M. Monitoring of metabolic adverse effects associated with atypical antipsychotics use in an outpatient psychiatric clinic. J Pharm Pract. 2019;32(4):388–93. doi: 10.1177/1088810117752712. Epub 2018 Jan 15. PMID: 29334810.

[21] Ayerbe L, Forgnone I, Foguet-Boreu Q, González E, Addo J, Ayis S. Disparities in the management of cardiovascular risk factors in patients with psychiatric disorders: a systematic review and meta-analysis. Psychol Med. 2018;48(16):2695–701. doi: 10.1017/S0033291718000302. Epub 2018 Mar 1. PMID: 29490716.

[22] Avella JR. Delphi panels: research design, procedures, advantages, and challenges. JIDS. 2016;11:305–21.

[23] Heald A, Pendlebury J, Anderson S, Narayan V, Guy M, Gibson M, et al. Lifestyle factors and the metabolic syndrome in schizophrenia: a cross-sectional study. Ann Gen Psychiatry. 2017;16:2. Epub 2017 Feb 15.
disorders: a systematic review and meta-analysis. PLoS Med. 2020;17(9):e1003284. doi: 10.1371/journal.pmed.1003284; PMID: 32925912; PMCID: PMC7489517.

[41] Heilberg IH, Nevåg R, Bälteskard L, Bramness JG, Hultman CM, Naess Ø, et al. Diagnostic tests and treatment procedures performed prior to cardiovascular death in individuals with severe mental illness. Acta Psychiatr Scand. 2020;141(5):439–51. doi: 10.1111/acps.13157. Epub 2020 Feb 29. PMID: 32022895; PMCID: PMC7317477.

[42] Bressee LG, Majumdar SR, Patton SB, Johnson JA. Utilization of general and specialized cardiac care by people with schizophrenia. Psychiatr Serv. 2012;63(3):237–42. doi: 10.1176/appi.ps.20100363. PMID: 22307876.

[43] Corrigan PW, Mittal D, Reaves CM, Haynes TF, Roos G, et al. Inequalities in healthcare provision for people with severe mental illness. J Psychopharmacol. 2010 Nov; 24(4 Suppl):61.

[44] Schuch FB, Vancampfort D, Rosenbaum S, Arango C, et al. Antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr Res. 2008;98:47–52. doi: 10.1016/j.schres.2007.12.009.

[45] Otvos JD, Newby DE, Arora NK, et al. Physical illness in patients with severe mental disorders: a global systematic review and meta-analysis. Lancet. 2014;384(9952):1753–66. doi: 10.1016/S0140-6736(14)61715-0.

[46] Scott-Ketefian N, Orsini N, Capone A, et al. Use of atypical antipsychotics in the elderly: a clinical review. Curr Med Prod Int. 2014;7(3):1363–73. doi: 10.1016/j.cmpi.2014.06.001.

[47] Pillinger T, McCutcheon RA, Balbus HE, et al. Antipsychotic drugs and reproductive hormones: relationship to body weight regulation. Pharmacol Biochem Behav. 1999;62(3):409–17.

[48] Miron IC, Baroané VC, Popescu F, Ionică F. Pharmacological mechanisms underlying the association of antipsychotics with metabolic disorders. Curr Health Sci J. 2014;40(1):12–7.

[49] Mathews J, Newcomer JW, Mathews JR, Fales CL, Pierce KJ, Akers BK, et al. Neural correlates of weight gain with olanzapine. Arch Gen Psychiatry. 2012;69(12):1226–37.

[50] Baptista T, Reyes D, Hernández L, Arumüham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64–77.

[51] Gareri P, Segura-García C, Manfredi VG, Bruni A, Ciambrone P, Cermi-VC, Popescu F, Ionică F. Pharmacological mechanisms underlying the association of antipsychotics with metabolic disorders. Curr Health Sci J. 2014;40(1):12–7.

[52] Baptista T, Reyes D, Hernández L, Arumüham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64–77.

[53] Mathews J, Newcomer JW, Mathews JR, Fales CL, Pierce KJ, Akers BK, et al. Neural correlates of weight gain with olanzapine. Arch Gen Psychiatry. 2012;69(12):1226–37.

[54] Pillinger T, McCutcheon RA, Balbus HE, et al. Antipsychotic drugs and reproductive hormones: relationship to body weight regulation. Pharmacol Biochem Behav. 1999;62(3):409–17.

[55] Gareri P, Segura-García C, Manfredi VG, Bruni A, Ciambrone P, Cermi-VC, Popescu F, Ionică F. Pharmacological mechanisms underlying the association of antipsychotics with metabolic disorders. Curr Health Sci J. 2014;40(1):12–7.

[56] Miron IC, Baroané VC, Popescu F, Ionică F. Pharmacological mechanisms underlying the association of antipsychotics with metabolic disorders. Curr Health Sci J. 2014;40(1):12–7.

[57] Pillinger T, McCutcheon RA, Balbus HE, et al. Antipsychotic drugs and reproductive hormones: relationship to body weight regulation. Pharmacol Biochem Behav. 1999;62(3):409–17.

[58] Mirdsah D, Tassier A, Daugnay C, Messinger S, Schurhoff F, Royer L, et al. Prevalence of and risk factors for extrapyramidal side effects of antipsychotics: results from the WHO World Health Survey. J Clin Psychiatry. 2011;72(12):1592–9.

[59] Morrato EH, Campagna EH, Brewer SE, Dickinson LM, DSK T, Miller BF, et al. Increased risk of diabetes mellitus among persons with psychotic symptoms: results from the WHO World Health Survey. J Clin Psychiatry. 2011;72(12):1592–9.

[60] Garrel-Al-Del Villar M, Carlos-Chillerón S, Ruiz-Candelita M, Sea F, Martinez-Gonzalez MA, et al. Healthy lifestyle and incidence of metabolic syndrome in the SUN cohort. Nutrients. 2018;11(1):65. Published 2018 Dec 30.